Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors.

Breast cancer research : BCR - 19 Nov 2013

Hudis Clifford, Swanton Charles, Janjigian Yelena Y, Lee Ray, Sutherland Stephanie, Lehman Robert, Chandarlapaty Sarat, Hamilton Nicola, Gajria Devika, Knowles James, Shah Jigna, Shannon Keith, Tetteh Ernestina, Sullivan Daniel M, Moreno Carolina, Yan Li, Han Hyo Sook

Abstract excerpt

INTRODUCTION: Trastuzumab is effective in human epidermal growth factor receptor 2 (HER2)-over-expressing breast and gastric cancers. However, patients may develop resistance through downstream signaling via the phosphatidylinositol 3-kinase (PI3K)/AKT pathway. This phase 1 trial was conducted to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Breast Neoplasms, Male

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Class I Phosphatidylinositol 3-Kinases

Share to Drug Administration Schedule

Share to Heterocyclic Compounds, 3-Ring

Share to Maximum Tolerated Dose

Share to Receptor, ErbB-2

Share to Trastuzumab

Source

Open in PubMed Open full text

Identifiers

PMID: 24252402
DOI: 10.1186/bcr3577
PMCID: PMC3979046

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24252402-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors.PMID 24252402Read ↗

HER2/PI3K/AKT pathway in HER2-positive breast cancer: A reviewSemantic proximity Read ↗

KN026, a Bispecific Anti-HER2 Antibody, Combined with KN046, an Anti-CTLA-4/PD-L1 Antibody, in Patients with HER2-positive Advanced Gastrointestinal Cancer: a multicenter, open-label, nonrandomized, phase Ib studySemantic proximity Read ↗

A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer.Semantic proximity Read ↗

The Biological Roles and Clinical Applications of the PI3K/AKT Pathway in Targeted Therapy Resistance in HER2-Positive Breast Cancer: A Comprehensive ReviewSemantic proximity Read ↗

A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.Semantic proximity Read ↗

Inavolisib-based Combination Therapy for the Treatment of PIK3CAMutated HR+/HER2- Breast Cancer: An Overview.Semantic proximity Read ↗

Molecular Pathways and Mechanisms of HER2 in Cancer TherapySemantic proximity Read ↗

Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.Semantic proximity Read ↗

Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment responseSemantic proximity Read ↗

Targeting ERBB2/HER2 genetic alterations: an expanding therapeutic opportunity in gastrointestinal cancers.Semantic proximity Read ↗

Antitumor Activity in <i>RAS</i> -Driven Tumors by Blocking AKT and MEKSemantic proximity Read ↗

The efficacy and safety of pyrotinib in treating HER2-positive metastatic breast cancer patients:A multi-center studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.